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OBJECTIVE: To test the hypothesis that intravenous use of methotrexate associated with lipid nanoemulsions
can achieve superior anti-inflammatory effects in the joints of rabbits with antigen-induced arthritis compared
with commercial methotrexate.
METHODS: Arthritis was induced in New Zealand rabbits sensitized with methylated bovine serum albumin and
subsequently intra-articularly injected with the antigen. A nanoemulsion of methotrexate labeled with
3H-cholesteryl ether (4 mg/kg methotrexate) was then intravenously injected into four rabbits to determine the
plasma decaying curves and the biodistribution of the methotrexate nanoemulsion by radioactive counting.
Additionally, the pharmacokinetics of the methotrexate nanoemulsion were determined by high-pressure liquid
chromatography. Twenty-four hours after arthritis induction, the animals were allocated into three groups,
with intravenous injection with saline solution (n=9), methotrexate nanoemulsion (0.5 mmol/kg methotrexate,
n=7), or commercial methotrexate (0.5 mmol/kg, n=4). The rabbits were sacrificed 24 h afterward. Synovial fluid
was then collected for protein leakage and cell content analyses and synovial membranes were collected for
histopathological analysis.
RESULTS: The methotrexate nanoemulsion was taken up mainly by the liver and the uptake by arthritic joints
was two-fold greater than that by control joints. The methotrexate nanoemulsion treatment reduced leukocyte
influx into the synovial fluid by nearly 65%; in particular, mononuclear and polymorphonuclear cells were
reduced by 47 and 72%, respectively. In contrast, cell influx was unaffected following treatment with
commercial methotrexate. Protein leakage into the arthritic knees of the rabbits was also more limited
following methotrexate nanoemulsion treatment than following commercial methotrexate treatment.
CONCLUSIONS: The intravenous methotrexate nanoemulsion showed anti-inflammatory effects on the synovia of
arthritic joints that were clearly superior to the effects of a commercial methotrexate preparation. This result is
conceivably due to greater methotrexate uptake by the joints when the drug is associated with a nanoemulsion.
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’ INTRODUCTION
In a recent study, we showed that a preparation consisting
of a methotrexate (MTX) derivative, namely, didodecyl MTX,
associated with a lipid nanoemulsion (LDE) had the ability to
markedly reduce inflammation when injected into rabbits
with antigen-induced arthritis (AIA) via the intra-articular
route. This effect was not attained when a commercial MTX
preparation at the same dose was intra-articularly injected
into rabbits (1). In fact, it is well known that MTX is not
effective when administered directly into a joint.
As shown byMaranhão et al. (2,3), the targeting capabilities of
the LDE system are attained by constructing LDEs with a
composition and structure that resemble those of low-density
lipoprotein (LDL), but without proteins. LDEs have affinity for
the different exchangeable apolipoproteins (apo) contained in the
plasma. One of the acquired apo molecules, or apo E, is
recognized by the LDL receptor and is thereby internalized into
cells via a receptor-mediated pathway. In cancer, atherosclerosis,
organ graft rejection, arthritis, and other diseases that include
proliferative and inflammatory processes, the lipoprotein recep-
tors are up-regulated, so LDEs and drugs associated with theDOI: 10.6061/clinics/2016(01)09
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nanoemulsions can be concentrated at targeted sites. The reduc-
tion in the toxicity of chemotherapeutic agents is remarkable, as
shown in experimental animals (4-6) and in clinical trials
enrolling patients with advanced cancer (7-9). Moreover, the
pharmacological action of the agents can be increased using this
drug targeting system (10,11).
MTX used in monotherapy or in combination with other
drugs is the drug of choice for the treatment of rheumatoid
arthritis (RA). RA is an autoimmune disease and one of the
principal causes of joint pain. RA is specifically characterized
by symmetric, peripheral polyarthritis. Inflammation of the
cells lining the synovium produces progressive erosion of the
synovial joints and often results in joint damage and
disability, along with several other systemic manifestations,
such as an increased incidence of ischemic heart disease.
MTX is a folic acid antagonist that has both anti-
proliferative and immunosuppressive actions. This drug also
has an extensive toxicity range and, in addition to its
relatively high toxicity, the variability and unpredictability of
its pharmacological action are also drawbacks to the use of
MTX in RA treatment. Due to poor response, high toxicity, or
both, approximately 26% of patients are expected to dis-
continue MTX treatment.
MTX is hydrophilic and cell uptake of this compound,
which depends on the folate receptor pathway, is poor,
constituting a limiting factor for the therapeutic effectiveness
of the drug and favoring the development of resistance to
treatment. Association with an LDE increases the uptake of
MTX by cultured neoplastic cells (K562 and HL60 cell
lineages) up to ninety-fold as the drug is internalized via
LDL-receptor-mediated endocytic pathways, instead of the
folate receptors (12). When injected into the inflamed joints of
rabbits with AIA, the uptake of a radioactive LDE by
arthritic joints is 2.5-fold greater than uptake by normal
joints. To achieve an optimum yield for MTX incorporation
into an LDE and to improve the stability of the preparation
of MTX associated with an LDE (LDE-MTX), MTX was
previously esterified with dodecyl bromide.
In view of the positive outcome of the experiments with
intra-articular LDE-MTX, experiments were designed to test
the hypothesis that the systemic use of LDE-MTX can also
achieve superior anti-inflammatory effects in comparison
with commercial MTX. The pharmacokinetics and biodis-
tribution of the novel formulation were determined in
control rabbits and the anti-inflammatory effects were
investigated in an antigen-induced RA rabbit model.
’ METHODS
The experiments were approved by the Animal Ethics
Committee of the Brazilian College of Experimental Animals
(CAPPesq 1093/07). Preparation of LDE-MTX was per-
formed as described in our previous study (1).
The pharmacokinetics of LDE-MTX were determined using
high-pressure liquid chromatography (HPLC) equipment
(Model SPD-10AV, Shimadzu Corporation, Kyoto, Japan
using a UV detector at 300 nm). Chromatographic separation
was achieved with a ShimPack C18 (2) (5mm, 15 cm x 6 mm)
analytical column (Phenomenex, Torrance, CA) and pro-
tected by a Luna C18 (2) guard cartridge. The mobile phase
was methanol at a flow rate of 1 mL/min for MTX. Stock
solutions of MTX were prepared at 0.1 mg/mL in methanol
and stored at 4oC. A stock solution of N-oleyl daunorubicin,
used as an internal standard (IS), was diluted in methanol
and stored at 4oC. Thawed blank plasma was spiked with the
0.1 mg/mL MTX stock solution to prepare a 5000 ng/mL
primary plasma stock, which was diluted further with blank
plasma to prepare plasma standards of 78.125, 156.25, 312.5,
625, 1250, 2500 and 5000 ng/mL. To each tube, 50 mL (5000
ng) of the IS was added and evaporated under nitrogen flow,
after which 300 mL of plasma standard and 600 mL of ethyl
acetoacetate:isopropyl alcohol (1:1) were added. The tubes
were vortexed for approximately 1 min and then centrifuged
at 3500 rpm for 15 min, after which 500 mL of supernatant
was transferred into a clean tube and evaporated at 36oC
under nitrogen. The residue was reconstituted with 50 mL of
methanol and 20 mL was injected onto the HPLC system to
set up the calibration curve.
Extraction of the MTX by precipitation with ethyl aceto-
acetate:isopropyl alcohol (1:1) was used for rabbit plasma
sample preparation. In particular, rabbit plasma standards or
samples (300 mL) containing MTX were aliquoted into 5 mL
tubes, spiked with 50 mL (5000 ng) of the IS and then mixed
with ethyl acetoacetate:isopropyl alcohol (1:1). The tubes were
vortexed for approximately 1 min and then centrifuged at
3500 rpm for 15 min, after which 500 mL of supernatant was
transferred into a clean tube and evaporated at 36oC under
nitrogen. The residue was reconstituted with 50 mL of the
mobile phase (methanol) and 20 mL was injected onto the
HPLC system at 1 mL/min. All calculations were performed
using the corrected peak area (peak area/migration time).
Calibration graphs were calculated by analyzing seven
different standard solutions of MTX using the IS method
and weighted linear regression (1/x).
The pharmacokinetics of MTX were determined in control
rabbits weighing approximately 3 kg. For this purpose, LDE-
MTX (2 mL total volume; 60 mg total lipids and 12 mg drug)
was injected as a single bolus into the marginal ear vein of
four rabbits for determination of the plasma decaying curves.
Blood samples were collected at pre-established intervals
over a 24 h period (5 and 15 min and 1, 2, 4, 8 and 24 h). The
plasma was separated by a 15 min centrifugation (3,000 g)
and the concentration of MTX was then determined by
HPLC. The pharmacokinetic parameters of MTX were
calculated using a multicompartmental model via computer
software (PK Solutions, Ashland, OH).
A 100 mL volume of LDE-MTX labeled with 14C-cholesteryl
ether (Perkin Elmer, Boston, MA) was intravenously injected
into the ear vein of 3 rabbits. The animals were kept in
individual cages, and 24 h after injection, they were
sacrificed. Fragments of liver, spleen, lung, heart, kidney,
muscle, pancreas and synovial tissue were excised and kept
in cold saline solution prior to lipid extraction with chloro-
form:methanol (2:1 v/v) (13). After lipid extraction, the sol-
vent was evaporated under nitrogen flow and resuspended
with 500 mL of chloroform:methanol (2:1 v/v) and half the
suspension was placed into vials with 5 mL of scintillation
solution (Packard BioScience, Groeningen, Netherlands). The
radioactivity was then measured with a Packard 1600 TR
liquid scintillation spectrometer (Palo Alto, CA).
Arthritis induction in New Zealand White rabbits was
performed as described in our previous study (1). Twenty-four
hours after arthritis induction, the animals were allocated into
three groups: one group was intravenously injected with saline
solution (300 mL, n=9); the second group, with LDE-MTX
(0.5 mmol/kg MTX, n=7); and the third group, with commercial
MTX (Miantrexs, Pfizer, New York, USA) (0.5 mmol/kg, n=4).
All preparations were injected in a single dose.
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The animals were sacrificed 48 h after arthritis induction.
Immediately after sacrifice, 2 mL of saline containing EDTA
(1 mg/mL) was injected into each knee joint. Synovial fluid
was collected with a needle, and the joint was then opened to
recover the remaining fluid. The collected synovial fluid was
diluted, and the total cell count was determined by light
microscopy. A differential cell count was also obtained using
smears prepared from cell pellets and stained with Giemsa.
To assess the vascular permeability, before the induction
of arthritis, the animals had been intravenously injected with
20 mg/kg Evans Blue in 2.5% saline solution. This dye binds
to plasma proteins, tagging macromolecule that cross the
endothelial barrier only when tissues are inflamed. The joint
fluid was centrifuged and the density was assessed using a
colorimetric method at 630 nm. The dye concentration in the
joint was estimated from a standard curve of Evans Blue
serial dilutions in saline solution. The results are expressed as
mg of protein/mL of synovial fluid.
’ RESULTS AND DISCUSSION
The standard and calibration curve equations showed that
the concentrations of MTX had a good linear correlation
(n=7, r2=0.999) for the standard solution of the drug in serum
samples in the concentration range of 78.125 to 5000 ng/mL.
Figure 1 shows the plasma kinetics of MTX associated with
the nanoemulsion after a bolus intravenous injection into the
rabbits, as followed over 24 h and determined by HPLC. The
kinetic parameters derived from the curve are displayed in
Figure 1.
Regarding the biodistribution of the LDE 3H-cholesterol
oleate ether in rabbits with AIA, the liver was the main tissue
with uptake, followed by the spleen. Uptake by arthritic
joints was two-fold greater than uptake in control saline-
injected joints, representing the tissue with the third highest
uptake (Figure 2).
Figure 3 shows the total and differential leukocyte counts
in the synovial fluid of the arthritic joints of the rabbits with
AIA treated with saline, commercial MTX or LDE-MTX.
Commercial MTX was ineffective in reducing the leukocyte
influx into the articular cavity. In contrast, the LDE-MTX
preparation reduced the leukocyte influx by nearly 65%;
specifically, LDE-MTX treatment reduced the mononuclear
(47%) and polymorphonuclear (72%) cell counts. The latter
are the predominant cell lineage in this phase of the
inflammatory process. The superior anti-inflammatory effi-
cacy of LDE-MTX was also shown by the data on the protein
leakage into the arthritic knees of the rabbits with AIA,
which was more limited in this treatment group compared
with both controls and commercial MTX-treated rabbits with
AIA (Figure 4).
Several drug delivery systems have been proposed to
improve the pharmacological index of MTX. Those systems
include liposomes, dendrimers, human serum albumin, solid
lipid nanoparticles, polymeric nanoparticles and micelles,
carbon nanotubes, and magnetic and gold nanoparticles. At
this stage, it is difficult to evaluate the advantages of one
system over the others because most of studies have been pre-
clinical testing reports. With respect to the MTX preparations
tested in subjects, namely, liposomes and human serum
albumin, there is still a lack of clinical evidence to support
their overall superiority (14,15). Being a low-cost oral
medication with widespread and long-standing clinical use
in RA and other rheumatic diseases, it is unlikely that
commercial MTX could be replaced by parenteral drug
delivery systems in the setting of chronic treatment of those
diseases. However, periods of treatment with drug delivery
systems that can increase the anti-inflammatory action of MTX
could reverse the stages of disease aggravation demanding
prompt intervention, especially when orally administered
medications are not effective.
The potential advantages of LDE-MTX are its lack of
immunogenicity and toxicity related to nanotechnological
Figure 1 - Decay curve of didodecyl MTX associated with an LDE after a bolus injection of 3.6 mg/kg drug and pharmacokinetic
parameters obtained from the curve. The concentration of MTX in the plasma was determined by HPLC. The analysis was performed
using a two-compartment open model. t1/2b: elimination half-life; AUC: area under the plasma concentration-time curve; Vss: volume
of distribution at steady state; CL: total body clearance. The results are expressed as the mean ± SE of data obtained from 4 rabbits.
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products, which have become major issues in the field. The
fact that the LDE constituent materials are only lipids, which
are present in the organism and are furnished by the
chemical industry; the low cost; and the ease of large-scale
production are also chief advantages.
It is noteworthy that the anti-inflammatory effects of
intravenous LDE-MTX injection, as illustrated in Figures 3
and 4, closely resemble those obtained following injection by
the intra-articular route (1). The overwhelming superiority of
the LDL-receptor-mediated endocytic pathway over the
folate receptor in promoting cell uptake of MTX (16)
may have been responsible for the marked improvement of
the drug’s anti-inflammatory properties when the LDE was
used as a carrier. In commercial MTX treatment, low cell
uptake via the folate receptor can conceivably facilitate
drug resistance. In view of the current results in the AIA
rabbit model, the possibility exists that use of an LDE as an
MTX carrier may also have the potential to disrupt drug
resistance mechanisms to allow the continuation of MTX
treatment.
Figure 2 - Tissue uptake of LDE labeled with 3H-cholesteryl oleyl ether. The tissue samples were excised for radioactivity counting 24 h
after intravenous injection of the labeled LDE into the rabbits with AIA. Contralateral synovia without arthritis induction were used as
controls.
Figure 3 - Leukocyte count (monocytes: white column; poly-
morphonuclear cells: gray column) in the synovial fluid of rabbits
48 h after AIA induction. The animals received commercial MTX
(0.5 mmol/kg), LDE-MTX (0.5 mmol/kg) or saline solution intrave-
nously 24 h after AIA induction. * po0.05 compared with the
control saline-treated rabbits with AIA. The results are expressed
as the mean ± SEM. The data have been subjected to repeated
analysis of variance. Post-analysis was conducted using Newman-
Keuls multiple comparison tests. In all analyses, po0.05 was
considered statistically significant.
Figure 4 - Vascular permeability, as assessed by the Evans Blue
method, in joint fluid collected from the joints of rabbits 48 h
after AIA induction. The animals received intravenous commer-
cial MTX (0.5 mmol/kg), LDE-MTX (0.5 mmol/kg) or saline solution
24 h after the induction of arthritis. * po0.05 compared with the
control saline-treated rabbits with AIA. The results are expressed
as the mean ± SEM. The data have been subjected to repeated
analysis of variance. Post-analysis was conducted using Newman-
Keuls multiple comparison tests. In all analyses, po0.05 was
considered statistically significant.
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